RNA Treatment for Pulmonary Vascular Disease: Mechanisms, Evidence, and Clinical Implications

Abstract

Pulmonary vascular disease (PVD) encompasses a spectrum of disorders characterized by pathological changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and, ultimately, right heart failure. With significant morbidity and mortality, novel targeted therapies are urgently needed. Recent years have seen a surge in interest in RNA-based therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and RNA aptamers, for the treatment of PVD. This review synthesizes current evidence on RNA therapeutics, elucidates their mechanisms of action, and discusses their translational potential and clinical implications, with a focus on pulmonary arterial hypertension (PAH) and related vascular pathologies.

Introduction

Pulmonary vascular disease remains a challenging clinical entity with limited therapeutic options, especially in advanced stages. Traditional pharmacological strategies target endothelial dysfunction, vasoconstriction, and smooth muscle proliferation. However, the molecular complexity of PVD pathobiology often renders these approaches insufficient. RNA-based therapeutics, designed to modulate gene expression at the transcript level, represent a promising new class of interventions with the potential for high specificity and disease-modifying effects. This article reviews the principles, current evidence, and future prospects of RNA-based treatments in PVD.

Epidemiology / Disease Burden

PVD, particularly pulmonary arterial hypertension (PAH), is a rare but devastating disease with a prevalence of approximately 15-50 cases per million adults. It disproportionately affects women and is associated with significant morbidity and a median survival of 3-5 years without effective therapy. Despite advances in supportive care and pharmacological management, mortality remains high, especially in patients with connective tissue disease-associated PAH and chronic thromboembolic pulmonary hypertension (CTEPH). The global burden is compounded by underdiagnosis and delayed intervention, emphasizing the imperative for novel therapies.

Pathophysiology

The pathogenesis of PVD is multifactorial, involving endothelial dysfunction, excessive smooth muscle cell proliferation, inflammation, and thrombosis. Key molecular pathways implicated include the bone morphogenetic protein receptor type II (BMPR2) signaling, nitric oxide, endothelin-1, and prostacyclin pathways. Dysregulation of gene expression, epigenetic modifications, and aberrant microRNA activity play pivotal roles in the progression of vascular remodeling and resistance to apoptosis. RNA-based therapies offer the unique advantage of targeting these upstream molecular derangements at the genetic and epigenetic levels.

Risk Factors

Risk factors for PVD include genetic mutations (e.g., BMPR2), connective tissue disorders, congenital heart disease, chronic lung disease, portal hypertension, and exposure to anorexigens or toxins. Familial forms of PAH are often linked to heritable mutations, while acquired forms may be precipitated by autoimmune, infectious, or environmental insults. Identification of modifiable and non-modifiable risk factors informs early screening and personalized treatment strategies.

Clinical Features

PVD typically presents with nonspecific symptoms such as progressive dyspnea, fatigue, chest pain, syncope, and features of right heart failure. Clinical findings may include elevated jugular venous pressure, peripheral edema, hepatomegaly, and a loud pulmonary component of the second heart sound. Diagnostic delay is common due to symptom overlap with other cardiopulmonary disorders, underscoring the need for heightened clinical suspicion.

Diagnosis

Diagnostic evaluation involves a combination of clinical assessment, echocardiography, pulmonary function tests, ventilation-perfusion scanning, right heart catheterization, and advanced imaging modalities. Biomarkers such as B-type natriuretic peptide (BNP) and circulating microRNAs are under investigation for their diagnostic and prognostic utility. Genetic testing for known mutations is recommended in familial or idiopathic cases, and may influence therapeutic decisions, particularly in the emerging era of RNA-targeted interventions.

Treatment & Management

Current management of PVD incorporates supportive measures (oxygen, diuretics), anticoagulation, and targeted pharmacotherapies such as endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin analogs. Despite improved survival, many patients experience disease progression, highlighting the need for disease-modifying treatments. Lung transplantation remains a consideration for end-stage disease but is limited by donor availability and perioperative risks.

Recent Advances / Emerging Therapies

RNA therapeutics are at the forefront of translational research in PVD. siRNAs and ASOs have demonstrated efficacy in preclinical models by silencing pathogenic gene expression, such as those involved in smooth muscle proliferation and inflammation. For example, siRNAs targeting BMPR2 and related signaling components show promise in restoring normal vascular architecture and function. Additionally, RNA aptamers—short, structured oligonucleotides that bind and inhibit specific proteins—are being explored to modulate key mediators of vasoconstriction and remodeling. MicroRNA mimics and inhibitors also represent an emerging class of therapeutics with the potential to fine-tune complex gene networks. Clinical trials evaluating safety, dosing, and efficacy of RNA-based drugs in PAH and other forms of PVD are ongoing, with initial results indicating favorable pharmacokinetics and target engagement.

Guideline Recommendations

Current international guidelines, such as those from the European Society of Cardiology (ESC) and European Respiratory Society (ERS), do not yet incorporate RNA-based therapies into standard practice due to the investigational status of these agents. However, guidelines emphasize the importance of enrolling eligible patients in clinical trials of novel therapeutics and recommend genetic counseling for heritable PAH. Ongoing updates are anticipated as trial data mature and regulatory approvals are obtained for RNA therapeutics in PVD.

Conclusion

RNA-based treatments represent a paradigm shift in the management of pulmonary vascular disease, offering precise, mechanism-based interventions that address the underlying molecular drivers of disease. While still largely in the experimental phase, early data are promising, and integration into clinical practice may transform outcomes for patients with otherwise refractory disease. Continued research, rigorous clinical trials, and multidisciplinary collaboration will be essential to fully realize the potential of RNA therapeutics in pulmonary vascular medicine.